Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-ketamine in Fibromyalgia
NCT04436250Terminated
- Sponsor
- Grand Hôpital de Charleroi
- Start
- Oct 2020
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, triple-blind trial of esketamine in fibromyalgia (FM), sponsored by Grand Hôpital de Charleroi. Primary endpoints: Pain relief at 12 weeks and Functional status at 12 weeks. Started Oct 2020; status: terminated.
02
Drugs
esketamine
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT04436250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04436250.